Erytech Pharma has acquired 1 company, including 1 in the last 5 years.
The Company’s most targeted sectors include leisure (100%).
60 Avenue Rockefeller Batiment Bioserra,
Lyon,
69008
France,
+33 4 78 74 44 38
www.erytech.com
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
|---|---|---|---|---|---|---|
| 2023-02-16 |
Pherecydes · Leisure
Romainville, France · www.pherecydes-pharma.com Pherecydes is a biotechnology company that develops treatments against resistant bacterial infections, responsible for many serious infections. The Company has developed an innovative approach, precision phage therapy, based on the use of phages, and natural bacteria viruses. It is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of hospital-acquired resistant infections: Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. Pherecydes was formed in 2006 and in based in Romainville, France. |
- | Merger | - |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
